Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorder) - Drugs in Development, 2021

October 2021 | 857 pages | ID: TFFA4308FE55EN
Global Markets Direct

Abstracts

Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorder) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Type 1 Diabetes - Drugs In Development, 2021, provides an overview of the Type 1 Diabetes (Metabolic Disorders) pipeline landscape.Type 1 diabetes (T1D) is an autoimmune disease in which a pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body’s immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. Risk factors of type 1 diabetes include genetics and family history, diseases of the pancreas and infection or illness. The signs and symptoms of type 1 diabetes include increased thirst and frequent urination, extreme hunger, weight loss, fatigue, irritability or unusual behavior.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Type 1 Diabetes - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Type 1 Diabetes (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 3, 10, 44, 40, 1, 5, 141, 35 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 2, 2, 1, 34 and 5 molecules, respectively.

Type 1 Diabetes (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Type 1 Diabetes (Metabolic Disorders).
• The pipeline guide reviews pipeline therapeutics for Type 1 Diabetes (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Type 1 Diabetes (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Type 1 Diabetes (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Type 1 Diabetes (Metabolic Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Type 1 Diabetes (Metabolic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Type 1 Diabetes (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Type 1 Diabetes - Overview
Type 1 Diabetes - Therapeutics Development
Type 1 Diabetes - Therapeutics Assessment
Type 1 Diabetes - Companies Involved in Therapeutics Development
Type 1 Diabetes - Drug Profiles
Type 1 Diabetes - Dormant Projects
Type 1 Diabetes - Discontinued Products
Type 1 Diabetes - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Abata Therapeutics, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Adocia SAS, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Aerami Therapeutics Inc, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Ahead Therapeutics SL, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Akston Biosciences Corp, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Algiax Pharmaceuticals GmbH, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Allele Biotechnology and Pharmaceuticals Inc, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Alpine Immune Sciences Inc, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Altheia Science SRL, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by ALTuCELL, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Amarna Therapeutics BV, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Amide Technologies Inc, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by AmideBio LLC, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Anokion SA, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Aphios Corp, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Apodemus AB, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by APT Therapeutics Inc, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Aptamer Sciences Inc, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Arecor Therapeutics Plc, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Ariddad Therapeutics SL, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Artery Therapeutics Inc, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Asake Biotechnology LLC, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by AstraZeneca Plc, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Asylia Therapeutics Inc, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by AVM Biotechnology LLC, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Avotres Inc, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Axxam SpA, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Beijing Advaccine Biotechnology Company Ltd, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Beta-Cell NV, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Medytox Inc, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Melior Pharmaceuticals I Inc, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Mercia Pharma Inc, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Merck & Co Inc, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Metavant Sciences Ltd, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by MidaSol Therapeutics LP, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Neovacs SA, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Neurodon LLC, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by NexImmune Inc, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by NextCell Pharma AB, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Novartis AG, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Novo Nordisk AS, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by OneVax LLC, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Op-T-Mune Inc, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Oramed Pharmaceuticals Inc, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Orgenesis Inc, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Orion BioScience Inc, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Orizuru Therapeutics Inc, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Otsuka Holdings Co Ltd, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Pancryos AS, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Panorama Researchama Research, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Paras Biopharmaceuticals Finland Oy, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Parvus Therapeutics Inc, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Pfizer Inc, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Veralox Therapeutics Inc, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Vertex Pharmaceuticals Inc, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by ViaCyte Inc, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by ViCapsys Inc, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Virtici LLC, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by vTv Therapeutics Inc, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Wockhardt Ltd, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by XERIS Pharmaceuticals Inc, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by XL-protein GmbH, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by XOMA Corp, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Youngene Therapeutics Co Ltd, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Zealand Pharma AS, 2021
Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Zucara Therapeutics Inc, 2021
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, 2021
Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021